SFM
VTGN icon

Sphera Funds Management’s VistaGen Therapeutics VTGN Stock Holding History

Sphera Funds Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$1.32M – 87
2022
Q2 		$1.32M Buy
+50,000
New +$1.77M 0.14% 47

Other funds holding VTGN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sphera Funds Management's VTGN Position: Q3 2025 in Review

Sphera Funds Management sold out of VistaGen Therapeutics (VTGN) in Q3 2025, closing a stake of 447,939 shares — an estimated $896K sold.

Sphera Funds Management first reported a position in VTGN in Q2 2016 and held it in 28 quarters. The position peaked at $12.9M in Q2 2021. 58 funds tracked by Wall St. Rank hold VTGN as of Q3 2025.

  • Sphera Funds Management reported no remaining VistaGen Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sphera Funds Management sold 447,939 VistaGen Therapeutics shares in Q3 2025, an estimated $896K.
  • Sphera Funds Management first reported a position in VistaGen Therapeutics in Q2 2016 and held it in 28 quarters.
  • Sphera Funds Management's VistaGen Therapeutics position peaked at $12.9M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.